2. MAPK/ERK Pathway Epigenetics Cell Cycle/DNA Damage PI3K/Akt/mTOR Apoptosis Cytoskeleton JAK/STAT Signaling
  3. p38 MAPK HDAC AMPK MDM-2/p53 Microtubule/Tubulin Pim Survivin Apoptosis
  4. WMJ-J-09

WMJ-J-09 is an HDAC inhibitor with IC50 values of 7.5 nM (HDAC1), 21.3 nM (HDAC2), 18.4 nM (HDAC3), 90.9 nM (HDAC8), 3.9 nM (HDAC6) and 8715.7 nM (HDAC4). WMJ-J-09 blocks the cell cycle and induces apoptosis in cancer cells. WMJ-J-09 induces cancer cell death through the LKB1-AMPK-p38MAPK-p63-survivin signaling cascade.WMJ-J-09 inhibits HDAC enzyme activity, leading to acetylation of key proteins and thereby regulating cancer cell death. WMJ-J-09 can be used in HCT116 cells and FaDu cells research[1][2].

For research use only. We do not sell to patients.

WMJ-J-09

WMJ-J-09 Chemical Structure

CAS No. : 2416914-29-7

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

WMJ-J-09 Related Antibodies

Top Publications Citing Use of Products

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

View All HDAC Isoform Specific Products:

View All Isoforms
HDAC HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2

View All AMPK Isoform Specific Products:

View All Isoforms
NUAK1 NUAK2 AMPK AMPK α1β1γ1 AMPK α2β1γ1 AMPK α1β2γ1 AMPK α2β2γ1 BRSK1 BRSK2 HUNK AMPKα

View All Pim Isoform Specific Products:

View All Isoforms
PIM1 PIM2 PIM3

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

WMJ-J-09 is an HDAC inhibitor with IC50 values of 7.5 nM (HDAC1), 21.3 nM (HDAC2), 18.4 nM (HDAC3), 90.9 nM (HDAC8), 3.9 nM (HDAC6) and 8715.7 nM (HDAC4). WMJ-J-09 blocks the cell cycle and induces apoptosis in cancer cells. WMJ-J-09 induces cancer cell death through the LKB1-AMPK-p38MAPK-p63-survivin signaling cascade.WMJ-J-09 inhibits HDAC enzyme activity, leading to acetylation of key proteins and thereby regulating cancer cell death. WMJ-J-09 can be used in HCT116 cells and FaDu cells research[1][2].

In Vitro

WMJ-J-09 (compound WMJ-J-09) (0-10 μM, 48 h, CRC cells) (0-20 μM, 72 h, HNSCC cells) selectively kills cancer cells in a concentration- and time-dependent manner, and exerts no significant toxicity on non-tumor FHC cells[1][2].

WMJ-J-09 (5 μM, 24 h, HCT116 cells) (10 μM, 48 h, FaDu cells) arrests the cell cycle of cancer cells at the G2/M phase and induces apoptosis[1][2].

WMJ-J-09 (5 μM, 24 h, HCT116 cells) (10 μM, 24 h, FaDu cells) disrupts microtubule assembly[1][2].

WMJ-J-09 (5 μM, 6-24 h, HCT116 cells) (10 μM, 24 h, FaDu cells) inhibits survivin at the transcriptional level[1][2].

WMJ-J-09 (0-10 μM, 24 h, HCT116 cells) (0-20 μM, 48 h, FaDu cells) regulates signaling pathways in cancer cells, inhibits HDACs to modulate key proteins, and promotes cancer cell apoptosis[1][2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

WMJ-J-09 Related Antibodies

Cell Viability Assay[1][2]

Cell Line: HCT116 cells, FHC cells; FaDu cells, SCC9 cells, SCC25 cells
Concentration: 0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM (HCT116 cells, FHC cells); 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 20 μM (FaDu cells, SCC9 cells, SCC25 cells)
Incubation Time: 48 h (HCT116 cells, FHC cells); 72 h (FaDu cells, SCC9 cells, SCC25 cells)
Result: Reduced the viability of CRC cells (with significant inhibition at 10 μM and an IC50 of approximately 5 μM).
Had the strongest inhibitory effect on cell viability at 10 μM, and the survival rate of FaDu cells dropped to about 30 % after treatment with 20 μM for 72 h.

Apoptosis Analysis[1][2]

Cell Line: HCT116 cells; FaDu cells
Concentration: 5 μM (HCT116 cells); 10 μM (FaDu cells)
Incubation Time: 24 h (HCT116 cells); 48 h (FaDu cells)
Result: Increased the proportion of early apoptotic (LR quadrant) and late apoptotic (UR quadrant) cells.
Increased cleaved caspase-3 and PARP cleavage fragments.
Significantly increased the proportion of sub-G1 phase (apoptotic cells), with approximately 40 % at 20 μM.

Cell Cycle Analysis[1][2]

Cell Line: HCT116 cells; FaDu cells
Concentration: 5 μM (HCT116 cells); 0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 20 μM (FaDu cells)
Incubation Time: 24 h
Result: Reduced the proportion of cells in the S phase and increased the proportion of cells in the G2/M phase and sub-G1 phase (apoptosis peak).
Increased the proportion of cells in the G2/M phase (from 12 % to 28 % at 10 μM) and decreased the number of cells in the S phase.

Immunofluorescence[1][2]

Cell Line: HCT116 cells; FaDu cells
Concentration: 5 μM (HCT116 cells); 10 μM (FaDu cells)
Incubation Time: 24 h
Result: Disrupted the cytoskeleton through α-tubulin acetylation.

RT-PCR[1][2]

Cell Line: HCT116 cells; FaDu cells
Concentration: 5 μM (HCT116 cells); 10 μM (FaDu cells)
Incubation Time: 6-24 h (HCT116 cells); 6 h (FaDu cells)
Result: Inhibited survivin expression at the transcriptional level.

Western Blot Analysis[1][2]

Cell Line: HCT116 cells, HCT116 p53-/- cells, HCT116-p53 wildtype cells; FaDu cells
Concentration: 0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM (HCT116 cells, HCT116 p53-/- cells, HCT116-p53 wildtype cells); 2.5 μM, 5 μM, 10 μM, 20 μM (FaDu cells)
Incubation Time: 24 h (HCT116 cells, HCT116 p53-/- cells, HCT116-p53 wildtype cells); 48 h (FaDu cells)
Result: Increased p21 protein, acetylated and phosphorylated p53, decreased survivin protein, and increased α-tubulin acetylation.
Activated phosphorylation of the LKB1/p38MAPK pathway.
Acetylated survivin and degraded it in the proteasome.
Increased p21 protein significantly, while cyclin D1 and survivin proteins decreased.
Increased the phosphorylation levels of LKB1 (Ser 428), AMPK (Thr 172), p38MAPK (Thr 180/Tyr 182), and p63 (Ser 160/162) over time, and increased cleaved caspase-3 and PARP (apoptosis markers).
In Vivo

WMJ-J-09 (compound WMJ-J-09) (20 mg/kg, i.p, daily for 19 days) inhibits CRC tumor growth by inhibiting cancer cell proliferation and is well tolerated in the HCT116 xenograft mice model[1].

WMJ-J-09 (20 mg/kg, i.p, daily for 23 days) inhibits the growth of HNSCC transplanted tumors and has good safety[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: HCT116 xenograft model established in nude male mice(4 weeks)[1]
Dosage: 20 mg/kg
Administration: Daily intraperitoneal injection (i.p.), at the corresponding doses for 19 days
Result: Inhibited tumor growth, with tumor volume and weight significantly lower than those in the control group.
Inhibited tumor proliferation, as indicated by reduced Ki67 immunohistochemical staining within the tumor.
Exhibited low toxicity, with no significant change in mouse body weight.
Animal Model: DaFu xenograft model established in nude male mice(4 weeks, 25g)[2]
Dosage: 20 mg/kg
Administration: Daily intraperitoneal injection (i.p.), at the corresponding doses for 23 days.
Result: Significantly inhibited tumor growth, with the average tumor weight in the treatment group lower than that in the control group.
Exhibited low toxicity, with no significant change in mouse body weight.
Molecular Weight

445.53

Formula

C22H27N3O5S
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(NO)CCCCCCC(NC1=CC(N(S(C2=CC=CC=C2)(=O)=O)CC3)=C3C=C1)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 250 mg/mL (561.13 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.2445 mL 11.2226 mL 22.4452 mL
5 mM 0.4489 mL 2.2445 mL 4.4890 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.2445 mL 11.2226 mL 22.4452 mL 56.1129 mL
5 mM 0.4489 mL 2.2445 mL 4.4890 mL 11.2226 mL
10 mM 0.2245 mL 1.1223 mL 2.2445 mL 5.6113 mL
15 mM 0.1496 mL 0.7482 mL 1.4963 mL 3.7409 mL
20 mM 0.1122 mL 0.5611 mL 1.1223 mL 2.8056 mL
25 mM 0.0898 mL 0.4489 mL 0.8978 mL 2.2445 mL
30 mM 0.0748 mL 0.3741 mL 0.7482 mL 1.8704 mL
40 mM 0.0561 mL 0.2806 mL 0.5611 mL 1.4028 mL
50 mM 0.0449 mL 0.2245 mL 0.4489 mL 1.1223 mL
60 mM 0.0374 mL 0.1870 mL 0.3741 mL 0.9352 mL
80 mM 0.0281 mL 0.1403 mL 0.2806 mL 0.7014 mL
100 mM 0.0224 mL 0.1122 mL 0.2245 mL 0.5611 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

WMJ-J-09 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

WMJ-J-092416914-29-7p38 MAPKHDACAMPKMDM-2/p53Microtubule/TubulinPimSurvivinApoptosisHistone deacetylasesAMP-activated protein kinasePim kinasescolorectal cancerhead and neck squamous cell carcinoma(HNSCC)FaDu cellsHCT116 cellsaliphatic hydroxamateliver kinase B1 (LKB1)Histone deacetylase (HDAC)p63P53survivinInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
WMJ-J-09
Cat. No.:
HY-174803
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.